Evidence map›Paper›PMID 39264453›Full record

SynthesisWorld journal of urology2024

Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy.

Anjali L Saripalli, Bhanu Prasad Venkatesulu, Nicholas G Nickols, Luca F Valle, Matthew M Harkenrider, Amar U Kishan, Abhishek A Solanki

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anjali L SaripalliDepartment of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Bhanu Prasad VenkatesuluDepartment of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Nicholas G NickolsDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Luca F ValleDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Matthew M HarkenriderDepartment of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Amar U KishanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Abhishek A SolankiDepartment of Radiation Oncology, Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA. asolanki@luc.edu.ORCID http://orcid.org/0009-0007-2186-2987

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntraprostatic recurrence (IRR) of prostate cancer after radiation therapy is increasingly identified. Our objective was to review the literature to determine the optimal workup for identifying IRR, the management options, and practical considerations for the delivery of re-irradiation as salvage local therapy.

methodsWe performed a systematic review of available publications and ongoing studies on the topics of IRR, with a focus on salvage re-irradiation.

resultsWork up of biochemically recurrent prostate cancer includes PSMA PET/CT and multiparametric MRI, followed by biopsy to confirm IRR. Management options include continued surveillance, palliative hormonal therapy, and salvage local therapy. Salvage local therapy can be delivered using re-irradiation with low dose rate brachytherapy, high dose rate (HDR) brachytherapy, and stereotactic body radiotherapy (SBRT), as well as non-radiation modalities, such as cryotherapy, high-intensity focused ultrasound, irreversible electroporation and radical prostatectomy. Data demonstrate that HDR brachytherapy and SBRT have similar efficacy compared to the other salvage local therapy modalities, while having more favorable side effect profiles. Recommendations for radiation therapy planning and delivery using HDR and SBRT based on the available literature are discussed.

conclusionSalvage re-irradiation is safe and effective and should be considered in patients with IRR.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsRe-IrradiationSalvage TherapyBrachytherapyHumansMalePractice Guidelines as TopicRadiosurgeryHigh dose rate brachytherapyProstate cancerRadiorecurrenceRe-irradiationSalvage local therapyStereotactic body radiotherapy

Identifiers

PMID39264453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.